Recombinant Human ARAF protein, GST-tagged
Cat.No. : | ARAF-32H |
Product Overview : | Recombinant Human ARAF(209-end) fused with GST tag at N-terminal was expressed in Insect cells. |
- Specification
- Gene Information
- Related Products
Description : | ARAF belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. ARAF play a critical role in cell growth and development (1).The N-terminal regulatory domain of ARAF interacted with the putative mitochondrial proteins TOM and TIM44. ARAF is expressed predominantly in urogenital tissues (2). The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. |
Source : | Insect cells |
Species : | Human |
Tag : | GST |
Form : | 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. |
Molecular Mass : | ~70 kDa |
Purity : | >70% |
Applications : | Western Blot |
Stability : | 1 year from date of shipment |
Storage : | Store product at –70 centigrade. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. |
Concentration : | 0.1μg/μl |
Gene Name : | ARAF v-raf murine sarcoma 3611 viral oncogene homolog [ Homo sapiens ] |
Official Symbol : | ARAF |
Synonyms : | ARAF; v-raf murine sarcoma 3611 viral oncogene homolog; ARAF1, v raf murine sarcoma 3611 viral oncogene homolog 1; serine/threonine-protein kinase A-Raf; Oncogene ARAF1; proto-oncogene Pks; proto-oncogene A-Raf-1; Ras-binding protein DA-Raf; v-raf murine sarcoma 3611 viral oncogene homolog 1; A-Raf proto-oncogene serine/threonine-protein kinase; PKS2; A-RAF; ARAF1; RAFA1; |
Gene ID : | 369 |
mRNA Refseq : | NM_001654 |
Protein Refseq : | NP_001645 |
MIM : | 311010 |
UniProt ID : | P10398 |
Chromosome Location : | Xp11.3-p11.23 |
Pathway : | Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem; Bladder cancer, organism-specific biosystem; Bladder cancer, conserved biosystem; Chronic myeloid leukemia, organism-specific biosystem; Chronic myeloid leukemia, conserved biosystem; Colorectal cancer, organism-specific biosystem; |
Function : | ATP binding; metal ion binding; nucleotide binding; protein binding; protein kinase activity; protein serine/threonine kinase activity; protein serine/threonine kinase activity; receptor signaling protein activity; |
Products Types
◆ Recombinant Protein | ||
ARAF-654M | Recombinant Mouse ARAF Protein, His (Fc)-Avi-tagged | +Inquiry |
Araf-823M | Recombinant Mouse Araf Protein, MYC/DDK-tagged | +Inquiry |
ARAF-239H | Recombinant Human ARAF Protein, His-tagged | +Inquiry |
ARAF-504H | Active Recombinant Human ARAF (YY301, 302DD) Mutation Protein, GST/His-tagged | +Inquiry |
ARAF-187H | Recombinant Human ARAF protein, GST-tagged | +Inquiry |
◆ Lysates | ||
ARAF-105HCL | Recombinant Human ARAF cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (24)
Ask a questionDysregulation of the ARAF protein is predominantly found in certain cancer types, including melanoma, colorectal cancer, lung cancer, and thyroid cancer. Mutations or alterations in the ARAF gene can occur, resulting in its dysregulated activity and contributing to the development and progression of these cancers.
Dysregulation of the ARAF protein is predominantly found in certain cancer types, including melanoma, colorectal cancer, lung cancer, and thyroid cancer. Mutations or alterations in the ARAF gene can occur, resulting in its dysregulated activity and contributing to the development and progression of these cancers.
Yes, several small molecule inhibitors that target the ARAF protein have been developed, such as sorafenib and RAF265. These drugs are primarily used in targeted cancer therapies and are designed to inhibit abnormal ARAF signaling in cancer cells.
Although the ARAF protein is primarily studied in the context of cancer and signaling pathways, it is also believed to have non-cancer-related functions. It may be involved in processes like neuronal development, cardiac function, and immune responses. Further research is needed to fully understand the breadth of its functions.
Although the ARAF protein is primarily studied in the context of cancer and signaling pathways, it is also believed to have non-cancer-related functions. It may be involved in processes like neuronal development, cardiac function, and immune responses. Further research is needed to fully understand the breadth of its functions.
Yes, the ARAF protein can be targeted for drug development. Small molecule inhibitors that specifically block the kinase activity of ARAF have been developed and studied as potential anti-cancer agents. These inhibitors aim to selectively inhibit abnormal ARAF signaling in cancer cells, while sparing normal cells.
The ARAF protein interacts with other proteins in the MAPK/ERK pathway to transmit signals and activate downstream effectors. It can form complexes with upstream proteins, such as growth factor receptors, to initiate signaling cascades. Additionally, it can interact with other kinases, scaffolding proteins, and adaptors to coordinate and amplify the signaling events.
The ARAF protein interacts with other proteins in the MAPK/ERK pathway to transmit signals and activate downstream effectors. It can form complexes with upstream proteins, such as growth factor receptors, to initiate signaling cascades. Additionally, it can interact with other kinases, scaffolding proteins, and adaptors to coordinate and amplify the signaling events.
Research on the ARAF protein can provide insights into its role in cancer development and signaling pathways. By understanding the molecular mechanisms of ARAF activation and its interactions with other proteins, novel therapeutic strategies can be developed. This knowledge can inform the design of more effective ARAF inhibitors, combination therapies, or alternative approaches to target ARAF dysregulation in cancer cells.
Research on the ARAF protein can provide insights into its role in cancer development and signaling pathways. By understanding the molecular mechanisms of ARAF activation and its interactions with other proteins, novel therapeutic strategies can be developed. This knowledge can inform the design of more effective ARAF inhibitors, combination therapies, or alternative approaches to target ARAF dysregulation in cancer cells.
The ARAF protein can contribute to cancer development through different mechanisms. Activating mutations in the ARAF gene can lead to aberrant activation of the MAPK/ERK signaling pathway, promoting uncontrolled cell growth, survival, and metastasis. Additionally, dysregulation of ARAF signaling can affect other cellular processes and contribute to tumor progression.
Yes, the ARAF protein plays a role in normal cellular processes and tissue homeostasis. It is involved in various developmental pathways and tissue-specific signaling cascades, contributing to normal growth, differentiation, and maintenance of tissues and organs.
There are ongoing clinical trials investigating the effectiveness and safety of ARAF inhibitors in cancer treatment. These trials are evaluating the potential of ARAF inhibitors as targeted therapies in specific cancer types and patient populations.
Yes, mutations in the ARAF gene have been identified in some rare genetic disorders. For example, germline ARAF mutations have been linked to Noonan syndrome, a genetic condition characterized by abnormal facial features, heart defects, short stature, and developmental delays.
Currently, there are no clinical trials specifically targeting the ARAF protein for cancer treatment listed on clinical trial databases like ClinicalTrials.gov. However, there may be preclinical studies or ongoing research investigating the potential of targeting ARAF in cancer therapy.
Currently, there are no clinical trials specifically targeting the ARAF protein for cancer treatment listed on clinical trial databases like ClinicalTrials.gov. However, there may be preclinical studies or ongoing research investigating the potential of targeting ARAF in cancer therapy.
ARAF mutations are relatively rare compared to other genes in the MAP kinase pathway, such as BRAF or KRAS. The frequency of ARAF mutations in cancer patients varies depending on the cancer type. For example, ARAF mutations are found in approximately 1-2% of melanomas and less frequently in other cancer types.
ARAF mutations are relatively rare compared to other genes in the MAP kinase pathway, such as BRAF or KRAS. The frequency of ARAF mutations in cancer patients varies depending on the cancer type. For example, ARAF mutations are found in approximately 1-2% of melanomas and less frequently in other cancer types.
Targeting the ARAF protein for therapy can have potential side effects and limitations. Since ARAF is involved in various cellular processes, inhibiting its activity can impact normal cell functions and lead to adverse effects. Additionally, resistance mechanisms can arise, rendering ARAF inhibitors less effective over time. Careful monitoring and combination therapies may be necessary to minimize side effects and overcome resistance.
Targeting the ARAF protein for therapy can have potential side effects and limitations. Since ARAF is involved in various cellular processes, inhibiting its activity can impact normal cell functions and lead to adverse effects. Additionally, resistance mechanisms can arise, rendering ARAF inhibitors less effective over time. Careful monitoring and combination therapies may be necessary to minimize side effects and overcome resistance.
Targeting the ARAF protein could have potential clinical applications in cancer therapy. Mutations or dysregulation of the ARAF gene have been found in certain cancers, and inhibiting ARAF activity with specific inhibitors may help control tumor growth or sensitize cancer cells to other treatment modalities.
Yes, the ARAF protein can be targeted in personalized medicine approaches. By identifying specific mutations or dysregulation in the ARAF gene, treatment strategies can be tailored to individual patients. This allows for the selection of therapeutic options that specifically target the abnormal ARAF signaling in each patient's cancer, potentially improving treatment outcomes.
Yes, the ARAF protein can be targeted in personalized medicine approaches. By identifying specific mutations or dysregulation in the ARAF gene, treatment strategies can be tailored to individual patients. This allows for the selection of therapeutic options that specifically target the abnormal ARAF signaling in each patient's cancer, potentially improving treatment outcomes.
The ARAF protein itself is not commonly used as a biomarker for disease diagnosis or prognosis. However, the presence or activity of ARAF, along with other components of the MAPK/ERK signaling pathway, may be assessed in certain cancer types to guide treatment decisions or assess treatment response.
Customer Reviews (8)
Write a reviewIts unique characteristics contribute to obtaining clear and detailed structural information, enabling researchers to unravel the intricate complexities of protein interactions and conformational changes.
The high-quality ARAF protein available from reliable manufacturers ensures accurate detection and quantification of ANO4 protein levels in samples, providing valuable insights into its biological roles and signaling pathways.
In addition to their expertise, the manufacturer's technical support team can assist in troubleshooting and optimizing the handling and application of the ARAF protein.
Its reliable and accurate performance ensures dependable results, contributing to the advancement of scientific knowledge in various disciplines.
In WB experiments, ARAF protein exhibits exceptional performance, making it an ideal tool for studying ANO4 protein expression, regulation, and potential functional changes.
ARAF protein demonstrates great utility in protein electron microscopy structure analysis.
By relying on the ARAF protein and the manufacturer's exceptional technical support, researchers can confidently pursue their experimental goals while knowing they have access to reliable resources and expert guidance.
The use of ARAF protein in this technique allows researchers to explore the intricate three-dimensional structure of the protein at a molecular level.
Ask a Question for All ARAF Products
Required fields are marked with *
My Review for All ARAF Products
Required fields are marked with *
Inquiry Basket